Less than 3 doses of the HPV vaccine – Review of efficacy against virological and disease end points

References

• Smolen KK, Gelinas L, Franzen L, Dobson S, Dawar M, Ogilvie G, Krajden M, Fortuno ES, III, Kollmann TR. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 2012; 30:3572-79; PMID:22469863; http://dx.doi.org/10.1016/j.vaccine.2012.03.051
   PubMed Web of Science ®Google Scholar
• Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30(Suppl 5):F123-38; PMID:23199956; http://dx.doi.org/10.1016/j.vaccine.2012.04.108
   PubMed Web of Science ®Google Scholar
• Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40:564-71; PMID:17531764; http://dx.doi.org/10.1016/j.jadohealth.2007.02.015
   PubMed Web of Science ®Google Scholar
• Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011; 7:1374-86; PMID:22048171; http://dx.doi.org/10.4161/hv.7.12.18322
   PubMed Web of Science ®Google Scholar
• Krajden M, Cook D, Yu A, Chow R, Mei W, McNeil S, Money D, Dionne M, Karunakaran KP, Palefsky JM, et al. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol 2011; 18:418-23; PMID:21248158; http://dx.doi.org/10.1128/CVI.00489-10
   PubMed Web of Science ®Google Scholar
• Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309:1793-802; PMID:23632723; http://dx.doi.org/10.1001/jama.2013.1625
   PubMed Web of Science ®Google Scholar
• Lazcano-Ponce E, Stanley M, Munoz N, Torres L, Cruz-Valdez A, Salmeron J, Rojas R, Herrero R, Hernandez-Avila M. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 2014; 32:725-32; PMID:24355090; http://dx.doi.org/10.1016/j.vaccine.2013.11.059
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, Gonzalez P, Solomon D, Jimenez S, Schiller JT, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103:1444-51; PMID:21908768; http://dx.doi.org/10.1093/jnci/djr319
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R. HPV vaccination: The most pragmatic cervical cancer primary prevention strategy. Int J Gynaecol Obstet 2015; 131(Suppl 1):S33-35; PMID:26433502; http://dx.doi.org/10.1016/j.ijgo.2015.02.014
   PubMedGoogle Scholar
• World Health Organization. Evidence based recommendations on Human Papilloma Virus (HPV) Vaccines Schedules. Background paper for SAGE discussions. http://www.who.int/immunization/sage/meetings/2014/april/1_HPV_Evidence_based_recommendationsWHO_with_Appendices2_3.pdf. 2014.
   Google Scholar
• Donken R, Knol MJ, Bogaards JA, van der Klis FR, Meijer CJ, de Melker HE. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis. J Infect 2015; 71:61-73; PMID:25709084; http://dx.doi.org/10.1016/j.jinf.2015.02.005
   PubMed Web of Science ®Google Scholar
• Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsague X, Rusche SA, Lukac S, Bryan JT, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118:2135-45; PMID:17079588; http://dx.doi.org/10.1542/peds.2006-0461
   PubMed Web of Science ®Google Scholar
• Gilca V, Sauvageau C, Boulianne N, De SG, Couillard M, Krajden M, Ouakki M, Murphy D, Trevisan A, Dionne M. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9–10 year-old girls according to 0-6 month schedule. Hum Vaccin Immunother 2014; 10:2438-45; PMID:25424952; http://dx.doi.org/10.4161/hv.29617
   PubMed Web of Science ®Google Scholar
• Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013; 31(Suppl 8):I1-31; PMID:24229716; http://dx.doi.org/10.1016/j.vaccine.2013.07.026
   PubMed Web of Science ®Google Scholar
• Leung TF, Liu AP, Lim FS, Thollot F, Oh HM, Lee BW, Rombo L, Tan NC, Rouzier R, Friel D, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial. Hum Vaccin Immunother 2015; 11:1689-702; PMID:26062002; http://dx.doi.org/10.1080/21645515.2015.1050570
   PubMed Web of Science ®Google Scholar
• Boxus M, Lockman L, Fochesato M, Lorin C, Thomas F, Giannini SL. Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule. Vaccine 2014; 32:3232-6; PMID:24731816; http://dx.doi.org/10.1016/j.vaccine.2014.04.005
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, Nene BM, Esmy PO, Joshi S, Poli URR, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncology 2015. (In press).
   Web of Science ®Google Scholar
• Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol 2015; 16:775-86; PMID:26071347; http://dx.doi.org/10.1016/S1470-2045(15)00047-9
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 2014; 32:5087-97; PMID:25018097; http://dx.doi.org/10.1016/j.vaccine.2014.06.038
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report: Cervarix. International non-proprietary name: Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed). 2013.
   Google Scholar
• Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Donaghy M. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014; 110:2804-11; PMID:24736582; http://dx.doi.org/10.1038/bjc.2014.198
   PubMed Web of Science ®Google Scholar
• Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199:805-14; PMID:19199546; http://dx.doi.org/10.1086/597071
   PubMed Web of Science ®Google Scholar
• Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44; PMID:21067976; http://dx.doi.org/10.1016/S1473-3099(10)70225-5
   PubMed Web of Science ®Google Scholar
• Blomberg M, Dehlendorff C, Munk C, Kjaer SK. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 2013; 57:929-34; PMID:23804192; http://dx.doi.org/10.1093/cid/cit436
   PubMed Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206: 1645-51; PMID:23087430; http://dx.doi.org/10.1093/infdis/jis590
   PubMed Web of Science ®Google Scholar
• Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013; 346:f2032; PMID:23599298; http://dx.doi.org/10.1136/bmj.f2032
   PubMed Web of Science ®Google Scholar
• Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, Netterlid E, Sparen P, Arnheim-Dahlstrom L. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA 2014; 311:597-603; PMID:24519299; http://dx.doi.org/10.1001/jama.2014.95
   PubMed Web of Science ®Google Scholar
• Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, Whiteman DC. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014; 348:g1458; PMID:24594809; http://dx.doi.org/10.1136/bmj.g1458
   PubMed Web of Science ®Google Scholar
• Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013; 11:227; PMID:24148310; http://dx.doi.org/10.1186/1741-7015-11-227
   PubMed Web of Science ®Google Scholar
• Brotherton JML, Malloy M, Budd AC, Saville M, Drennan KT, Gertig DM. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: observational cohort of young women in Australia. Papillomavirus Research 2015; 1:59-73; http://dx.doi.org/10.1016/j.pvr.2015.05.005
   Web of Science ®Google Scholar
• Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26:6844-51; PMID:18930097; http://dx.doi.org/10.1016/j.vaccine.2008.09.073
   PubMed Web of Science ®Google Scholar
• IARC. Primary end-points for prophylactic HPV Vaccine Trials: IARC Working Group Report Volume 7. 2014.
   Google Scholar
• Lamontagne DS, Thiem VD, Huong VM, Tang Y, Neuzil KM. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis 2013; 208:1325-34; PMID:23901077; http://dx.doi.org/10.1093/infdis/jit363
   PubMed Web of Science ®Google Scholar
• Wang JW, Hung CF, Huh WK, Trimble CL, Roden RB. Immunoprevention of human papillomavirus-associated malignancies. Cancer Prev Res (Phila) 2015; 8:95-104; PMID:25488410; http://dx.doi.org/10.1158/1940-6207.CAPR-14-0311
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet. 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4
   PubMed Web of Science ®Google Scholar